“…The current WHO grading system comprises three grades as follows: most meningiomas are slow growing, are generally considered benign tumors, and correspond to grade I (typical meningiomas); about 10% of cases are classi®ed as grade II (atypical) or anaplastic/malignant (grade III), exhibiting more aggressive clinical behaviour, with a higher risk of recurrence when compared to typical grade I meningiomas (Kleihues et al, 1993). These neoplasms are usually sporadic, but a few families have been described with multiple tumors inherited in an autosomal dominant fashion (Memon, 1980;Battersby et al, 1986;Butti et al, 1989;Domenicucci et al, 1989), and they also occur in as many as half of the patients with the dominantly inherited familial neuro®bromatosis type 2 syndrome (NF2) (Martuza and Eldridge, 1988). Using positional cloning approaches, the candidate gene for NF2 has been isolated from chromosome 22q12 region (Rouleau et al, 1993;Trofatter et al, 1993), and mutations have been observed in both germ-line of NF2 patients and in about 30% of sporadic meningiomas Lekanne-Deprez et al, 1994;Merel et al, 1995;Papi et al, 1995;De Vitis et al, 1996;Harada et al, 1996).…”